Statistik Asas
| LEI | 54930015RAQRRZ5ZGJ91 |
| CIK | 875320 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vertex Pharmaceuticals Incorporated
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 5, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vert |
|
| August 4, 2025 |
Vertex Reports Second Quarter 2025 Financial Results — Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion — — Continued strong execution of CASGEVY®, ALYFTREK® and JOURNAVX® launches — — Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2025 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2025 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 14, 2025 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 6, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Ver |
|
| May 6, 2025 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of this 7th day of February, 2025, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Charles F. Wagner, Jr. (the “Executive”). W IT N E S S E T H WHEREAS, the Company and the Executive desire that the |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2025 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation) |
|
| May 5, 2025 |
CORRESP May 5, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 5, 2025 |
Vertex Reports First Quarter 2025 Financial Results — Total revenue of $2.77 billion, a 3% increase compared to Q1 2024; raised the low end of total revenue guidance by $100 million to a new range of $11.85 to $12 billion — — Strong progress with CASGEVY®, ALYFTREK™ and JOURNAVX™ launches — — Povetacicept (pove) IgAN Phase 3 interim analysis (IA) cohort fully enrolled and zimislecel Phase 3 progra |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 x Filed by the Registrant o Filed by a Party other than the Registrant Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy State |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 28, 2025 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| February 13, 2025 |
Vertex Pharmaceuticals Incorporated Insider Trading Policy. * Exhibit 19.1 Vertex Pharmaceuticals Incorporated Insider Trading Policy 1.PURPOSE Vertex Pharmaceuticals Incorporated (“Vertex”) has adopted this Insider Trading Policy in order to take an active role in the prevention of insider trading violations by its directors, employees, and related individuals and entities. Vertex prohibits the misuse of material nonpublic information in the trading of secu |
|
| February 13, 2025 |
Vertex Pharmaceuticals Non-Employee Board Compensation.* Exhibit 10.43 Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 annual retainer Management Development & Compensation Committee Chair $25,000 annual retainer Corporate Governance & Nominating Committee Chair $25,000 annual retainer Science & Technology Committee Chair $25,000 annu |
|
| February 13, 2025 |
Amended and Restated By-Laws of Vertex Pharmaceuticals Incorporated. Exhibit 3.2 AMENDED AND RESTATED BY-LAWS of VERTEX PHARMACEUTICALS INCORPORATED Effective as of February 11, 2025 ARTICLE I SHAREHOLDERS Section 1. Annual Meeting. The annual meeting of the shareholders shall be held on such date within six months after the end of the fiscal year of Vertex Pharmaceuticals Incorporated (the “Corporation”) as the Board of Directors of the Corporation (the “Board of |
|
| February 13, 2025 |
, by and between Vertex Pharmaceuticals Incorporated and Charles F. Wagner, Jr.* Exhibit 10.39 February 7, 2025 Charles F. Wagner [Address] RE: Change of Control Agreement Dear Charles: You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to continue to provide you with the following “change of control” benefits to help ensure that if the Company becomes involved in a “change of control” |
|
| February 13, 2025 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (9) Vertex Pharmaceuticals (Cayman III) Limited, a Cayman Islands company (4) Vertex Pharmaceuticals (Cayman 509) Lim |
|
| February 13, 2025 |
Exhibit 10.22 VERTEX PHARMACEUTICALS INCORPORATED 2013 STOCK AND OPTION PLAN Restricted Stock Unit Award (with Performance Conditions) This Agreement sets forth the terms and conditions of a Restricted Stock Unit Award granted pursuant to the provisions of the 2013 Stock and Option Plan (as it may be amended or restated, the “Plan”) of Vertex Pharmaceuticals Incorporated (the “Company”) to the Par |
|
| February 13, 2025 |
, by and between Vertex Pharmaceuticals Incorporated and Charles F. Wagner, Jr.* Exhibit 10.38 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of this 7th day of February, 2025, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Charles F. Wagner, Jr. (the “Executive”). W IT N E S S E T H WHEREAS, the Company and the Executive desire that th |
|
| February 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Inc |
|
| February 13, 2025 |
Exhibit 10.21 VERTEX PHARMACEUTICALS INCORPORATED 2013 STOCK AND OPTION PLAN Restricted Stock Unit Award This Agreement sets forth the terms and conditions of a Restricted Stock Unit Award granted pursuant to the provisions of the 2013 Stock and Option Plan (as it may be amended or restated, the “Plan”) of Vertex Pharmaceuticals Incorporated (the “Company”) to the Participant whose name appears be |
|
| February 13, 2025 |
Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Vertex Pharmaceuticals Incorporated (the “Company” or “Vertex”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”). DESCRIPTION OF CAPITAL STOCK The f |
|
| February 13, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025 As filed with the Securities and Exchange Commission on February 13, 2025 Registration No. |
|
| February 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vertex Pharmaceuticals Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to Be Paid Equity Common stock, $0. |
|
| February 12, 2025 |
Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. |
|
| February 10, 2025 |
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results — Full year product revenue of $11. |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 4, 2025 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| December 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 20, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpor |
|
| November 5, 2024 |
Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. |
|
| November 5, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 |
|
| November 5, 2024 |
Exhibit 10.3 AMENDMENT NO. 3 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 3 is made and entered into effective as of November 1, 2024 (the “Effective Date”) to the employment agreement dated as of April 1, 2020, as most recently amended effective as of February 8, 2023 (the “Employment Agreement”), between Vertex Pharmaceuticals Incorporated (the “Company”) and Jeffrey M. Leiden, MD., Ph.D. (the “Ex |
|
| November 5, 2024 |
Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. |
|
| November 4, 2024 |
Vertex Reports Third Quarter 2024 Financial Results — Product revenue of $2.77 billion, a 12% increase compared to Q3 2023 — — Raising full-year product revenue guidance to $10.8 billion to $10.9 billion — — Preparing for two potential near-term launches: vanzacaftor triple in CF and suzetrigine (VX-548) for moderate-to-severe acute pain — — Pipeline progress continuing with three additional progr |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 4, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 15, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporat |
|
| August 2, 2024 |
dated June 20, 2024, by and between Vertex Phar Exhibit 10.1 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT is entered into as of June 20, 2024 (this “Agreement”), by and between VERTEX PHARMACEUTICALS INCORPORATED, a Massachusetts corporation (the “Company”), and Bank of America, N.A., as administrative agent (in such capacity, together with its successors and permitted assigns in such capacity, the “Administrativ |
|
| August 2, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vert |
|
| August 1, 2024 |
Vertex Reports Second Quarter 2024 Financial Results — Product revenue of $2.65 billion, a 6% increase compared to Q2 2023 — — Company raises full year product revenue guidance to $10.65 to $10.85 billion — — FDA accepted NDA for vanzacaftor triple in CF with Priority Review and PDUFA target action date of January 2, 2025; additionally, MAA submissions validated in EU and U.K. — — FDA accepted NDA |
|
| August 1, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| June 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 27, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporatio |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 20, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 3) ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of Filing Pe |
|
| May 15, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 15, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 10, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of |
|
| May 8, 2024 |
Transcript of Vertex Q1 Earnings Call on May 6, 2024. Exhibit 99.(a)(5)(F) ● Event Details Date: 2024-05-06 Company: Vertex Pharmaceuticals, Inc. Ticker: VRTX-US ● Company Participants Susie Lisa - Vertex Pharmaceuticals, Inc., Senior Vice President-Investor Relations Reshma Kewalramani - Vertex Pharmaceuticals, Inc., President, Chief Executive Officer & Director Stuart A. Arbuckle - Vertex Pharmaceuticals, Inc., Executive Vice President & Chief Oper |
|
| May 8, 2024 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of |
|
| May 8, 2024 |
Slide Excerpts from Vertex Q1 Earnings Call Presentation on May 6, 2024. EX-99.(a)(5)(E) Exhibit 99.(a)(5)(E) FIRST QUARTER 2024 FINANCIAL RESULTS MAY 6, 2024 ©2024 Vertex Pharmaceuticals Incorporated SAFE HARBOR STATEMENT & NON-GAAP FINANCIAL MEASURES This presentation contains forward-looking statements that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-lookin |
|
| May 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Ver |
|
| May 6, 2024 |
Vertex Reports First Quarter 2024 Financial Results — Product revenue of $2.69 billion, a 13% increase compared to Q1 2023; reiterated full year 2024 financial guidance, including product revenue guidance of $10.55 to $10.75 billion — — Submitted NDA and MAA filings for vanzacaftor triple in CF to FDA and EMA, respectively — —Initiated rolling NDA submission for suzetrigine (VX-548) in moderate-to |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 6, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation) |
|
| April 22, 2024 |
Exhibit (a)(1)(D) Offer to Purchase All Outstanding Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Mutual Confidentiality Agreement, dated February 14, 2024, between Alpine and Vertex. Exhibit (d)(4) MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (this “Agreement”) is made effective as of the date of the last signature below (the “Effective Date”), by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation with offices at 50 Northern Avenue, Boston, Massachusetts 02210 (“Vertex”) and Alpine Immune Sciences, Inc. |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ALPINE IMMUNE SCIENCES, INC. (Name of Subject Company (Issuer)) ADAMS MERGER SUB, INC. (Offeror) a wholly owned subsidiary of VERTEX PHARMACEUTICALS INCORPORATED (Parent of Offeror) (Names of Filing Persons (identifying |
|
| April 22, 2024 |
Form of Letter of Transmittal (including Internal Revenue Service Form W-9) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Offer to Purchase, dated April 22, 2024 Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Exhibit 107 Calculation of Filing Fee Tables SCHEDULE TO ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees Exhibit (a)(1)(C) Offer to Purchase All Outstanding Shares of Common Stock of ALPINE IMMUNE SCIENCES, INC. |
|
| April 22, 2024 |
Mutual Confidentiality Agreement, dated March 21, 2024, between Alpine and Vertex. Exhibit (d)(5) Execution Copy MUTUAL CONFIDENTIALITY AGREEMENT This Mutual Confidentiality Agreement (this “Agreement”) is entered into as of March 21, 2024, by and between Vertex Pharmaceuticals Incorporated (‘‘you”) and Alpine Immune Sciences, Inc. |
|
| April 22, 2024 |
Summary Advertisement, as published in The New York Times on April 22, 2024 Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| April 16, 2024 |
Notice of Exempt Solicitation NAME OF REGISTRANT: Vertex Pharmaceuticals Incorporated NAME OF PERSONS RELYING ON EXEMPTION: Arjuna Capital ADDRESS OF PERSON RELYING ON EXEMPTION: 13 Elm St. |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (State or other jurisdiction of incorporat |
|
| April 11, 2024 |
Exhibit 99.1 APRIL 10, 2024 / 8:30PM, VRTX.OQ - Vertex Pharmaceuticals Inc Enters Into Agreement to Acquire Alpine Immune Sciences- Conference Call CORPORATE PARTICIPANTS Charles F. Wagner Vertex Pharmaceuticals Incorporated - Executive VP & CFO Jeffrey Marc Leiden Vertex Pharmaceuticals Incorporated - Executive Chairman Reshma Kewalramani Vertex Pharmaceuticals Incorporated - CEO, President & Dir |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) MASSACHUSETTS 000-19319 04-3039129 (State or other jurisdiction of incorporat |
|
| April 11, 2024 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Alpine Immune Sciences, Inc. (Name of Subject Company (issuer)) Adams Merger Sub, Inc. (Offeror) a wholly-owned subsidiary of Vertex Pharmaceuticals Incorporated (Parent of Offeror) (Names of Filing Persons (ide |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 Alpine Immune Sciences, Inc. (Name of Subject Company (issuer)) Adams Merger Sub, Inc. (Offeror) a wholly-owned subsidiary of Vertex Pharmaceuticals Incorporated (Parent of Offeror) (Names of Filing Persons (identifying |
|
| April 10, 2024 |
Exhibit 99.2 VERTEX PHARMACEUTICALS ACQUISITION OF ALPINE IMMUNE SCIENCES APRIL 10, 2024 ©2024 Vertex Phag rlm oba acle .v uti rtx c.a clo s m Incorporated This presentation contains forward-looking statements related to Vertex, Alpine and the proposed acquisition of Alpine by Vertex (the “Transaction”) that are subject to risks, uncertainties and other factors. While Vertex believes the forward-l |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Vertex Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92532F100 (CUSIP Number) March 29, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 15, 2024 |
Vertex Pharmaceuticals Employee Compensation Plan.* Exhibit 10.36 Vertex Employee Compensation Plan On an annual basis, the Management Development and Compensation Committee of our Board of Directors adopts an employee compensation plan for our officers and other employees, including our named executive officers, together with performance goals for that fiscal year. The plan addresses three components of employee compensation—base salary, performan |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Inc |
|
| February 15, 2024 |
Exhibit 10.7 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. AMENDMENT NO. 1 TO THE AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This AMENDMENT NO. 1 TO THE AMENDED AND RESTATED JOINT DEVELOPMENT AN |
|
| February 15, 2024 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (2) Vertex Pharmaceuticals (Cayman III) Limited, a Cayman Islands company (4) Vertex Pharmaceuticals (Cayman 509) Lim |
|
| February 15, 2024 |
Policy Relating to Recovery of Erroneously Awarded Compensation Exhibit 97.1 VERTEX PHARMACEUTICALS INCORPORATED POLICY FOR RECOUPMENT OF INCENTIVE COMPENSATION 1.Introduction In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the regulations thereunder, the Board of Directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) has adopted a policy (the “Policy”) providing for the Compan |
|
| February 13, 2024 |
VRTX / Vertex Pharmaceuticals Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02209-vertexpharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Vertex Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 92532F100 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate bo |
|
| February 9, 2024 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Vertex Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92532F100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 5, 2024 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| February 5, 2024 |
Vertex Reports Fourth Quarter and Full Year 2023 Financial Results — Full year product revenue of $9. |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 8, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 5, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| November 7, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 |
|
| November 6, 2023 |
Vertex Reports Third Quarter 2023 Financial Results — Product revenue of $2.48 billion, a 6% increase compared to Q3 2022 — — Company raises full year 2023 product revenue guidance to approximately $9.85 billion — — U.S. FDA Advisory Committee meeting for exa-cel in SCD completed; PDUFA date for exa-cel in SCD is December 8, 2023 — —Pipeline continues to advance: Phase 3 data in CF and acute pain |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 6, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| October 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 3, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporat |
|
| August 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vert |
|
| August 1, 2023 |
Vertex Reports Second Quarter 2023 Financial Results — Product revenue of $2.49 billion, a 14% increase compared to Q2 2022 — — Company raises full year 2023 product revenue guidance to $9.7 to $9.8 billion — — FDA has accepted the exa-cel BLAs in both severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT); Priority Review granted for SCD with PDUFA date of December 8, 2 |
|
| August 1, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 1, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KYMERA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) Jonathan Biller Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 (617) 341-6100 |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 17, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 2, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Ver |
|
| May 1, 2023 |
Vertex Reports First Quarter 2023 Financial Results — Product revenue of $2.37 billion, a 13% increase compared to Q1 2022 — — Company reiterates full year 2023 financial guidance, including product revenue guidance of $9.55 to $9.7 billion — — TRIKAFTA approved in U.S. for children with cystic fibrosis 2 to 5 years of age — — Pipeline advancement continues with completion of rolling BLA submissio |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 1, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation) |
|
| April 6, 2023 |
Notice of Annual Meeting of Shareholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Defin |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Defin |
|
| February 13, 2023 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vertex Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92532F100 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 10, 2023 |
Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Vertex Pharmaceuticals Incorporated (the “Company” or “Vertex”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”). DESCRIPTION OF CAPITAL STOCK The f |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Inc |
|
| February 10, 2023 |
Vertex Pharmaceuticals Employee Compensation Plan.* Exhibit 10.37 Vertex Employee Compensation Plan On an annual basis, the Management Development and Compensation Committee of our Board of Directors adopts an employee compensation plan for our officers and other employees, including our named executive officers, together with performance goals for that fiscal year. The plan addresses three components of employee compensation—base salary, performan |
|
| February 10, 2023 |
Exhibit 10.23 AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 2 is made and entered into effective as of February 8, 2023 (the “Effective Date”) to the employment agreement dated as of April 1, 2020, as amended effective as of February 7, 2022 (the “Employment Agreement”), between Vertex Pharmaceuticals Incorporated (the “Company”) and Jeffrey M. Leiden, MD., Ph.D. (the “Executive”). NO |
|
| February 10, 2023 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (2) Vertex Pharmaceuticals (Cayman III) Limited, a Cayman Islands company (4) Vertex Pharmaceuticals (Cayman 509) Lim |
|
| February 10, 2023 |
Amended and Restated By-Laws of Vertex Pharmaceuticals Incorporated. Exhibit 3.2 AMENDED AND RESTATED BY-LAWS of VERTEX PHARMACEUTICALS INCORPORATED Effective as of February 8, 2023 ARTICLE I SHAREHOLDERS Section 1. Annual Meeting. The annual meeting of the shareholders shall be held on such date within six months after the end of the fiscal year of Vertex Pharmaceuticals Incorporated (the “Corporation”) as the Board of Directors of the Corporation (the “Board of D |
|
| February 9, 2023 |
VRTX / Vertex Pharmaceuticals Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv02181-vertexpharmaceutical.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Vertex Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 92532F100 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo |
|
| February 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 7, 2023 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| February 7, 2023 |
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results — Full year product revenue of $8. |
|
| October 28, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 |
|
| October 27, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 27, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| October 27, 2022 |
Vertex Reports Third Quarter 2022 Financial Results ? Product revenue of $2.33 billion, an 18% increase compared to Q3 2021 ? ? Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion ? ? Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities: Initiating global exa-cel regulatory submissions for Sickle Cell Disease and |
|
| October 4, 2022 |
United States securities and exchange commission logo October 4, 2022 Reshma Kewalramani Chief Executive Officer and President Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 Re: Vertex Pharmaceuticals Incorporated Definitive Proxy Statement on Schedule 14A Filed April 7, 2022 File No. |
|
| September 26, 2022 |
Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, MA 02210-1862 Tel: 617-341-6100 www. |
|
| September 20, 2022 |
United States securities and exchange commission logo September 20, 2022 Reshma Kewalramani Chief Executive Officer and President Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 Re: Vertex Pharmaceuticals Incorporated Definitive Proxy Statement on Schedule 14A Filed April 7, 2022 File No. |
|
| August 5, 2022 |
As filed with the Securities and Exchange Commission on August 5, 2022 S-8 1 a2022s-8x2013plan.htm S-8 As filed with the Securities and Exchange Commission on August 5, 2022 Registration No. 333— UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) Massachusetts (State or other jurisdiction of i |
|
| August 5, 2022 |
Exhibit 10.1 Published CUSIP Numbers: 92534MAM5 (Deal) 92534MAN3 (Revolver) CREDIT AGREEMENT Dated as of July 1, 2022 among VERTEX PHARMACEUTICALS INCORPORATED, as the Company, a Borrower, and a Guarantor, THE SUBSIDIARIES OF THE COMPANY PARTY HERETO, as Designated Foreign Borrowers and/or Guarantors, BANK OF AMERICA, N.A., as the Administrative Agent, the Swingline Lender and an L/C Issuer, CITIB |
|
| August 5, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Vertex Pharmaceuticals Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(2) Equity Common stock, $0. |
|
| August 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vert |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 4, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| August 4, 2022 |
Vertex Reports Second Quarter 2022 Financial Results ? Product revenues of $2.20 billion, a 22% increase compared to Q2 2021 ? ? Company raises full year 2022 product revenue guidance to $8.6 to $8.8 billion ? ? Recent exa-cel and VX-880 clinical data presentations demonstrate transformative potential for patients with sickle cell disease, beta thalassemia and type 1 diabetes? ? Multiple clinical |
|
| July 11, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 9, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| July 11, 2022 |
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes -ViaCyte brings tools, technologies and assets with potential to accelerate development of VX-880, Vertex’s fully differentiated, insulin-producing, stem cell derived islets - -ViaCyte to be acquired for $320 million in cash- BOSTON (BUSINESS WIRE) - July 11, 2022 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has entered into a definitive agreement under which Vertex will acquire ViaCyte, a privately held biotechnology company focused on delivering novel stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D), for $320 million in cash. |
|
| July 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 1, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 23, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 18, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 18, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| May 6, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Ver |
|
| May 5, 2022 |
Vertex Reports First Quarter 2022 Financial Results ? Product revenues of $2.10 billion, a 22% increase compared to Q1 2021 ? ? Company reiterates full year 2022 product revenue guidance of $8.4 to $8.6 billion ? ? Mid- and late-stage clinical pipeline now spans 6 disease areas ? BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first |
|
| May 5, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 5, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation) |
|
| May 5, 2022 |
Exhibit 99.2 Vertex Pharmaceuticals Incorporated Reconciliation of Reported to Revised GAAP to Non-GAAP Net Income (in millions, except per share amounts) (unaudited) Starting in the first quarter of 2022, Vertex no longer excludes research and development charges resulting from upfront or contingent milestone payments in connection with collaborations, asset acquisitions and/or licensing of third |
|
| April 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Defin |
|
| April 7, 2022 |
DEF 14A 1 lvrtx2022def14a.htm VERTEX PHARMACEUTICALS INC - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only |
|
| February 10, 2022 |
VRTX / Vertex Pharmaceuticals Incorporated / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Vertex Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 92532F100 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 9, 2022 |
EXHIBIT 10.24 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 is made and entered into effective as of February 7, 2022 (the ?Effective Date?) to the employment agreement dated as of April 1, 2020 (the ?Employment Agreement?), between Vertex Pharmaceuticals Incorporated (the ?Company?) and Jeffrey M. Leiden, MD., Ph.D. (the ?Executive?). NOW, THEREFORE, in consideration of the mutual |
|
| February 9, 2022 |
Exhibit 10.37 VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210 TEL. 617.341.6100 August 1, 2020 Nia Tatsis [Address] RE: Change of Control Agreement Dear Nia: You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the ?Company?). As a result, the Company would like to provide you with the following ?change of control? benefits to help ensu |
|
| February 9, 2022 |
Exhibit 10.36 EMPLOYMENT AGREEMENT This Employment Agreement (this ?Agreement?) is made and entered into as of this 1st day of August, 2020, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the ?Company?), and Nia Tatsis (the ?Executive?). W IT N E S S E T H WHEREAS, the Company and the Executive desire that the Executive be |
|
| February 9, 2022 |
As filed with the Securities and Exchange Commission on February 9, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 9, 2022 Registration No. |
|
| February 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Inc |
|
| February 9, 2022 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Securities Corporation, a Massachusetts corporation Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (3) Vertex Pharmaceuticals (Cayman III) Limited, a Cayman |
|
| February 9, 2022 |
Vertex Pharmaceuticals Non-Employee Board Compensation.* Exhibit 10.39 Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 annual retainer Management Development & Compensation Committee Chair $25,000 annual retainer Corporate Governance & Nominating Committee Chair $25,000 annual retainer Science & Technology Committee Chair $25,000 annu |
|
| February 9, 2022 |
EX-FILING FEES 4 d671945dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Vertex Pharmaceuticals Incorporated (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title(1) Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggreg |
|
| January 26, 2022 |
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results -Full year product revenues of $7. |
|
| January 26, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 26, 2022 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| November 3, 2021 |
EX-10.4 5 a2021q310-qexhibit104.htm EX-10.4 Exhibit 10.4 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. Amendment No. 7 Research, Development and Commercialization Agreement, Dated May 24, 2004 by and between Vertex Pharmac |
|
| November 3, 2021 |
Exhibit 10.1 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Vertex Pharmaceuticals Incorporated and Cystic Fibrosis Foundation Therapeutics Incorporated Research |
|
| November 3, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 |
|
| November 3, 2021 |
Exhibit 10.3 Execution Copy Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. AMENDMENT NO. 5 to RESEARCH, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT, DATED MAY 24, 2004, by and between VERTEX PHARMACEUTICALS INCORPORATED and |
|
| November 3, 2021 |
Exhibit 10.2 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. AMENDMENT NO. 1 TO RESEARCH, DEVELOPMENT AND COMMECIALIZATION AGREEMENT (the ?Existing Agreement?) DATED MAY 24, 2004 BY AND BETWEEN VERTEX PHARMACEUTICALS INCORPO |
|
| November 2, 2021 |
Vertex Reports Third-Quarter 2021 Financial Results -Product revenues of $1.98 billion, a 29% increase compared to Q3 2020- -Company raises full-year 2021 guidance for product revenues to $7.4 to $7.5 billion- -Broad pipeline advancing with recent progress marked by unprecedented VX-880 clinical results in T1D; Phase 2 clinical results for VX-147 expected this quarter and for VX-548 in Q1 2022- BO |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 2, 2021 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| July 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vert |
|
| July 30, 2021 |
Lease, dated May 5, 2011, between Fifty Northern Avenue LLC and Vertex Pharmaceuticals Incorporated. Exhibit 10.2 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. EXECUTION COPY FIFTY NORTHERN AVENUE LLC AND VERTEX PHARMACEUTICALS INCORPORATED LEASE FOR 50 NORTHERN AVENUE (PARCEL A ? FAN PIER) BOSTON, MASSACHUSETTS FIFTY NOR |
|
| July 30, 2021 |
Exhibit 10.1 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. AMENDED AND RESTATED JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CRIS |
|
| July 30, 2021 |
Exhibit 10.3 Certain confidential information contained in this document, marked by [***], has been omitted because it is not material and would likely cause competitive harm to Vertex Pharmaceuticals Incorporated if publicly disclosed. EXECUTION COPY ELEVEN FAN PIER BOULEVARD LLC AND VERTEX PHARMACEUTICALS INCORPORATED LEASE FOR 11 FAN PIER BOULEVARD (PARCEL B ? FAN PIER) BOSTON, MASSACHUSETTS EL |
|
| July 29, 2021 |
Vertex Reports Second-Quarter 2021 Financial Results -Product revenues of $1.79 billion, an 18% increase compared to Q2 2020- - Company raises full-year 2021 guidance for product revenues to $7.2 to $7.4B- ?Phase 3 study of next-in-class triple combination for CF to begin in the second half of 2021; multiple additional clinical milestones across the pipeline expected in the next 6 to 9 months - BO |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 29, 2021 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporatio |
|
| June 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 23, 2021 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporatio |
|
| May 19, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) May 19, 2021 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporation |
|
| April 30, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Ver |
|
| April 29, 2021 |
PX14A6G 1 j429212px14a6g.htm NAME OF REGISTRANT: VERTEX PHARMACEUTICALS INC. NAME OF PERSON RELYING ON EXEMPTION: FRIENDS FIDUCIARY CORPORATION ADDRESS OF PERSON RELYING ON EXEMPTION: 1700 MARKET STREET, SUITE 1535, PHILADELPHIA, PA 19103 April 29, 2021 To Vertex Shareholders: Friends Fiduciary Corporation seeks your support FOR Proposal 4 at the stockholder meeting on May 19, 2021. The proposal a |
|
| April 29, 2021 |
Vertex Reports First-Quarter 2021 Financial Results -Product revenues of $1.72 billion, a 14% increase compared to Q1 2020- - Company advancing clinical programs in six additional diseases beyond cystic fibrosis- -Multiple Phase 2 proof-of-concept study results expected in 2021 - BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2021 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| April 20, 2021 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 16, 2021 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| April 8, 2021 |
- VERTEX PHARMACEUTICALS INC - DEFA14A DEFA14A 1 lvrtxdefa14a.htm VERTEX PHARMACEUTICALS INC - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Defin |
|
| February 11, 2021 |
Vertex Pharmaceuticals Non-Employee Board Compensation.* EX-10.41 4 a10k2020-exhibit1041.htm EX-10.41 Exhibit 10.41 Vertex Pharmaceuticals Incorporated Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 annual retainer Management Development & Compensation Committee Chair $25,000 annual retainer Corporate Governance & Nominating Committee Chair $20,000 annual retainer Scie |
|
| February 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Inc |
|
| February 11, 2021 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. EX-21.1 5 a10k2020-exhibit211.htm EX-21.1 Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Securities Corporation, a Massachusetts corporation Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (3) Vertex Pharm |
|
| February 11, 2021 |
EX-10.10 3 a10k2020-exhibit1010.htm EX-10.10 Exhibit 10.10 FIRST AMENDMENT TO CREDIT AGREEMENT This FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of December 29, 2020 (this “Amendment”), by and among Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), the other Loan Parties (as defined in the Existing Credit Agreement (as defined below)) party hereto, the Lenders (as |
|
| February 11, 2021 |
Exhibit 10.6 [***] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would cause competitive harm if publicly disclosed. JOINT DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BETWEEN VERTEX PHARMACEUTICALS INCORPORATED VERTEX PHARMACEUTICALS (EUROPE) LIMITED AND CRISPR THERAPEUTICS AG CRISPR THERAPEUTICS LIM |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Vertex Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 92532F100 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 1, 2021 |
EX-99.1 2 ex-991q42020.htm EX-99.1 Vertex Reports Full-Year and Fourth-Quarter 2020 Financial Results -Full-year 2020 GAAP product revenues of $6.20 billion- -Full-year 2020 non-GAAP product revenues of $6.20 billion, a 55% increase compared to full-year 2019- -Company provides full-year 2021 product revenue guidance of $6.7 to $6.9 billion- BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VR |
|
| February 1, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 1, 2021 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| November 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 20, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpor |
|
| October 30, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 |
|
| October 30, 2020 |
Exhibit 10.1 EXECUTION Published CUSIP Numbers: 92534MAK9 (Deal) 92534MAL7 (Revolver) CREDIT AGREEMENT Dated as of September 18, 2020 among VERTEX PHARMACEUTICALS INCORPORATED, as the Company and a Borrower, THE SUBSIDIARIES OF THE COMPANY PARTY HERETO, as Designated Foreign Borrowers or Subsidiary Guarantors, BANK OF AMERICA, N.A., as Administrative Agent, Swingline Lender and an L/C Issuer, and |
|
| October 29, 2020 |
Vertex Reports Third-Quarter 2020 Financial Results -Product revenues of $1.54 billion, a 62% increase compared to Q3 2019- -Company raises revenue guidance; now expects 2020 product revenues of $6.0 to $6.2 billion- BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2020 and revised upward its full-ye |
|
| October 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 29, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| September 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 18, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpo |
|
| September 3, 2020 |
KYMR / Kymera Therapeutics, Inc. / VERTEX PHARMACEUTICALS INC / MA - SC 13D Activist Investment SC 13D 1 schedule13dsept2020.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* KYMERA THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 501575104 (CUSIP Number) Michael Parini Vertex Pharmaceuticals Incorporated 50 Northern Avenue Bost |
|
| July 31, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vert |
|
| July 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 30, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporatio |
|
| July 30, 2020 |
Vertex Reports Second-Quarter 2020 Financial Results -Product revenues of $1.52 billion, a 62% increase compared to Q2 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.7 to $5.9 billion- BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the second quarter ended June 30, 2020 and revised upward its full-year 2020 |
|
| June 3, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporatio |
|
| June 2, 2020 |
LOBBYING DISCLOSURE AT VERTEX PHARMACEUTICALS Commentary on Shareholder Resolution Seeking Increased Lobbying Disclosure Friends Fiduciary Corporation seeks your support1 for Item 4 on the Vertex Pharmaceuticals Incorporated’s (“Vertex” or “the Company”) 2020 proxy ballot. |
|
| May 1, 2020 |
Amended and Restated By-Laws of Vertex Pharmaceuticals Incorporated. AMENDED AND RESTATED BY-LAWS of VERTEX PHARMACEUTICALS INCORPORATED ARTICLE I STOCKHOLDERS Section 1. |
|
| May 1, 2020 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Ver |
|
| April 29, 2020 |
Vertex Reports First-Quarter 2020 Financial Results -Product revenues of $1.52 billion, a 77% increase compared to Q1 2019- -Company raises revenue guidance; now expects 2020 CF revenues of $5.3 to $5.6 billion- BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2020 and revised upward its full-year 2020 f |
|
| April 29, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) April 29, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| April 28, 2020 |
- VERTEX PHARMACEUTICALS INC - DEFA14A DEFA14A 1 lvrtx2020defa14a.htm VERTEX PHARMACEUTICALS INC - DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only |
|
| April 28, 2020 |
- VERTEX PHARMACEUTICALS INC - DEFA14A VERTEX PHARMACEUTICALS INCORPORATED DEFA 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 28, 2020 |
- VERTEX PHARMACEUTICALS INC - DEF 14A DEF 14A 1 lvrtx2020def14a.htm VERTEX PHARMACEUTICALS INC - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only |
|
| April 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorporati |
|
| April 1, 2020 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of April 1, 2020 (the “Effective Date”) between Vertex Pharmaceuticals Incorporated (the “Company”) and Jeffrey M. Leiden, M.D., Ph.D. (the “Executive”) and is effective as of March 31, 2020. WHEREAS, the Company and the Executive previously entered into an amended and restated employment agr |
|
| February 13, 2020 |
Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value CHF 0. |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) Michael Parini Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 (617) 341-6100 |
|
| February 13, 2020 |
Form of Restricted Stock Unit Agreement Under 2013 Stock and Option Plan.* Exhibit 10.17 VERTEX PHARMACEUTICALS INCORPORATED 2013 STOCK AND OPTION PLAN Form of Restricted Stock Unit Award This Agreement sets forth the terms and conditions of a Restricted Stock Unit Award granted pursuant to the provisions of the 2013 Stock and Option Plan (as it may be amended or restated, the “Plan”) of Vertex Pharmaceuticals Incorporated (the “Company”) to the Participant whose name ap |
|
| February 13, 2020 |
Exhibit 10.35 May 18, 2012 Paul M. Silva 23 Tammer Lane Hopkinton, MA 01748 RE: Amended and Restated Change of Control Agreement Dear Paul: You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to provide you with the following “change of control” benefits to help ensure that if the Company becomes involved in |
|
| February 13, 2020 |
Exhibit 4.2 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Vertex Pharmaceuticals Incorporated (the “Company” or “Vertex”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): our common stock, par value $0.01 per share (“Common Stock”). DESCRIPTION OF CAPITAL STOCK The f |
|
| February 13, 2020 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Securities Corporation, a Massachusetts corporation Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (3) Vertex Pharmaceuticals (Cayman II) Limited, a Cayman I |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Inc |
|
| February 12, 2020 |
VRTX / Vertex Pharmaceuticals Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Vertex Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 92532F100 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| January 30, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) January 30, 2020 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| January 30, 2020 |
Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results - Full-year 2019 total GAAP product revenues of $4. |
|
| November 26, 2019 |
CRSP / CRISPR Therapeutics AG / VERTEX PHARMACEUTICALS INC / MA - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) Michael Parini Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 (617) 341-6100 (N |
|
| October 31, 2019 |
EXECUTION CREDIT AGREEMENT Dated as of September 17, 2019 among VERTEX PHARMACEUTICALS INCORPORATED, as the Company and a Borrower, THE SUBSIDIARIES OF THE COMPANY PARTY HERETO as Designated Foreign Borrowers or Subsidiary Guarantors, BANK OF AMERICA, N. |
|
| October 31, 2019 |
Execution Version AGREEMENT AND PLAN OF MERGER DATED AS OF AUGUST 30, 2019 BY AND AMONG VERTEX PHARMACEUTICALS INCORPORATED, VERTEX DISC INC. |
|
| October 31, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 V |
|
| October 30, 2019 |
Vertex Reports Third-Quarter 2019 Financial Results - Product revenues of $950 million, a 21% increase compared to Q3 2018 - - Continued progression of pipeline of investigational medicines in multiple diseases - BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third quarter ended September 30, 2019 and reiterated its full-year 2019 total product revenue guidance. |
|
| October 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 30, 2019 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| October 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2019 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpor |
|
| October 21, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2019 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpor |
|
| September 17, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2019 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorp |
|
| September 3, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2019 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 000-19319 04-3039129 (State or other jurisdiction of incorpora |
|
| August 1, 2019 |
VRTX / Vertex Pharmaceuticals Inc. S-8 - - S-8 As filed with the Securities and Exchange Commission on August 1, 2019 Registration No. |
|
| August 1, 2019 |
VRTX / Vertex Pharmaceuticals Inc. S-8 - - S-8 S-8 1 s-8xespp.htm S-8 As filed with the Securities and Exchange Commission on August 1, 2019 Registration No. 333— UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) Massachusetts (State or other jurisdiction of incorporat |
|
| August 1, 2019 |
EX-10.1 2 a2019q210-qexhibit101.htm EXHIBIT 10.1 Execution Version AGREEMENT AND PLAN OF MERGER AMONG VERTEX PHARMACEUTICALS INCORPORATED, VXP MERGER SUB, INC., EXONICS THERAPEUTICS, INC., AND SHAREHOLDER REPRESENTATIVE SERVICES LLC, SOLELY IN ITS CAPACITY AS SHAREHOLDERS’ REPRESENTATIVE DATED AS OF JUNE 6, 2019 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKET |
|
| August 1, 2019 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex |
|
| July 31, 2019 |
Vertex Reports Second-Quarter 2019 Financial Results - Product revenues of $940 million, a 25% increase compared to 2018 - - Company increases full-year 2019 total product revenue guidance to $3. |
|
| July 31, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8-kq22019.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorpo |
|
| July 25, 2019 |
Execution Copy AMENDMENT NO. 1 TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This AMENDMENT NO. 1 is made and entered into effective as of July 24, 2019 (the “Effective Date”) to the amended and restated employment agreement dated as of November 30, 2016 (the “Employment Agreement”), between Vertex Pharmaceuticals Incorporated (the “Company”) and Jeffrey M. Leiden, MD., Ph.D. (the “Executive”). WHE |
|
| July 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 24, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319 (Commis |
|
| July 25, 2019 |
VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE • BOSTON, MA 02210 TEL. 617.341.6100 July 24, 2019 Reshma Kewalramani 174 Winding River Road Wellesley, MA 02482 RE: Change of Control Agreement Dear Reshma: You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to provide you with the following “change of |
|
| July 25, 2019 |
Execution Copy EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of this 24th day of July, 2019, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Reshma Kewalramani (the “Executive”). |
|
| June 7, 2019 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319 (Commiss |
|
| June 7, 2019 |
SC 13D/A 1 sc13d-a3.htm SCHEDULE 13D, AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) Michael Parini Vertex Pharmaceuticals Incorporated 50 Northe |
|
| June 7, 2019 |
Exhibit 4 Execution Version STANDSTILL AGREEMENT THIS STANDSTILL AGREEMENT (this “Agreement”) is made and entered into as of June 6, 2019 (the “Effective Date”), by and between CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) organized under the laws of Switzerland (the “Company”), and Vertex Pharmaceuticals Incorporated (“Vertex Parent”) and Vertex Pharmaceuticals (Europe) Limited (“Vertex UK” and, together with Vertex Parent, “Vertex”). |
|
| June 5, 2019 |
8-K 1 a8-k2019annualmeeting.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction |
|
| May 21, 2019 |
VRTX / Vertex Pharmaceuticals Inc. PX14A6G - - Vertex Pharmaceuticals Incorporated (VRTX) Item 7 Friends Fiduciary Corporation Friends Fiduciary Corporation seeks your support1 for Item 7 on the Vertex Pharmaceuticals Incorporated’s (“Vertex” or “the Company”) 2019 proxy ballot. |
|
| May 6, 2019 |
VRTX / Vertex Pharmaceuticals Inc. PX14A6G PROXY MEMORANDUM To: Vertex Pharmaceutical Shareholders Subject: Shareholder resolution on extent to which risks related to public concern over drug pricing are integrated into incentive compensation policies for senior executives Date: May 6, 2019 Contact: Catherine Rowan, Director, Socially Responsible Investments, Trinity Health At the upcoming Vertex Pharmaceuticals Incorporated (“Vertex” or “the “Company”) annual shareholders’ meeting on June 5, 2019, shareholders will have the opportunity to vote on a Proposal (the “Proposal”) asking Vertex to disclose how it considers risks stemming from public concern over high drug prices in setting incentive pay arrangements for senior executives. |
|
| May 1, 2019 |
Exhibit 10.2 VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210 TEL. 617.341.6100 March 28, 2019 Charles F. Wagner, Jr. 22 Quarry Road Medfield, MA 02052 RE: Change of Control Agreement Dear Mr. Wagner: You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to provide you with the following |
|
| May 1, 2019 |
10-Q 1 a2019q110-q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commissi |
|
| May 1, 2019 |
Exhibit 10.2 VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210 TEL. 617.341.6100 March 28, 2019 Charles F. Wagner, Jr. 22 Quarry Road Medfield, MA 02052 RE: Change of Control Agreement Dear Mr. Wagner: You are a key member of the senior management team of Vertex Pharmaceuticals Incorporated (the “Company”). As a result, the Company would like to provide you with the following |
|
| May 1, 2019 |
EX-10.1 2 a2019q110-qexhibit101.htm EXHIBIT 10.1 Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (this “Agreement”) is made and entered into as of this 28th day of March, 2019, by and between Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (together with its successors and assigns, the “Company”), and Charles F. Wagner, Jr. (the “Executive”). W IT N E S S E T H WHEREAS |
|
| April 30, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a8-kq12019.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorp |
|
| April 30, 2019 |
EX-99.1 2 ex-991q12019.htm EXHIBIT 99.1 Vertex Reports First-Quarter 2019 Financial Results - First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018- - First-quarter 2019 GAAP operating income increased 115% to $277 million; non-GAAP operating income increased 81% to $377 million - - On track to choose best triple combination regimen in Q2 2019; NDA su |
|
| April 26, 2019 |
Vertex Pharmaceuticals Incorporated Employee Stock Purchase Plan.* DEF 14A 1 lvrt2019def14a.htm VERTEX PHARMACEUTICALS INC - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only ( |
|
| April 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319 (Commi |
|
| February 22, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319 (Co |
|
| February 13, 2019 |
VRTX / Vertex Pharmaceuticals Inc. S-3ASR S-3ASR 1 s-32019.htm S-3ASR As filed with the Securities and Exchange Commission on February 13, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) Massachusetts 04-3039129 (State or other jurisdi |
|
| February 13, 2019 |
Vertex Pharmaceuticals Non-Employee Board Compensation.* Exhibit 10.39 Vertex Pharmaceuticals Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 annual retainer Management Development & Compensation Committee Chair $25,000 annual retainer Corporate Governance & Nominating Committee Chair $20,000 annual retainer Science & Technology Committee Chair $20,000 annual retainer C |
|
| February 13, 2019 |
VRTX / Vertex Pharmaceuticals Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19319 Vertex Pharmaceuticals Inc |
|
| February 13, 2019 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Securities Corporation, a Massachusetts corporation Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (3) Vertex Pharmaceuticals (Cayman II) Limited, a Cayman I |
|
| February 13, 2019 |
Vertex Pharmaceuticals Non-Employee Board Compensation.* Exhibit 10.39 Vertex Pharmaceuticals Annual Non-Employee Board Compensation Annual Retainer $100,000 Committee Chair Compensation Audit & Finance Committee Chair $30,000 annual retainer Management Development & Compensation Committee Chair $25,000 annual retainer Corporate Governance & Nominating Committee Chair $20,000 annual retainer Science & Technology Committee Chair $20,000 annual retainer C |
|
| February 13, 2019 |
Subsidiaries of Vertex Pharmaceuticals Incorporated. Exhibit 21.1 Subsidiaries of Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals (San Diego) LLC, a Delaware limited liability company Vertex Securities Corporation, a Massachusetts corporation Vertex Pharmaceuticals (Distribution) Incorporated, a Delaware corporation Vertex Pharmaceuticals (Cayman) Limited, a Cayman Islands company (3) Vertex Pharmaceuticals (Cayman II) Limited, a Cayman I |
|
| February 11, 2019 |
VRTX / Vertex Pharmaceuticals Inc. / VANGUARD GROUP INC Passive Investment SC 13G/A 1 vertexpharmaceuticalsinc.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5 )* Name of issuer: Vertex Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 92532F100 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appropriate box to designate the |
|
| February 5, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319 (Com |
|
| February 5, 2019 |
Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results - Full-year 2018 CF product revenues of $3. |
|
| January 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 23, 2019 VERTEX PHARMACEUTICALS INCORPORATED (Exact name of registrant as specified in its charter) MASSACHUSETTS (State or other jurisdiction of incorporation) 000-19319 (Com |
|
| December 28, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) Ian F. Smith Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 (617) 341-6100 (Na |
|
| December 26, 2018 |
SC 13D/A 1 sc13da.htm SC 13D/A FOR VERTEX PHARMACEUTICALS INC / MA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) Ian F. Smith Vertex Pharmaceuticals Incorporate |
|
| December 21, 2018 |
CRSP / CRISPR Therapeutics AG / VERTEX PHARMACEUTICALS INC / MA - SCHEDULE 13D Activist Investment SC 13D 1 sc13d.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CRISPR THERAPEUTICS AG (Name of Issuer) Common Shares, par value CHF 0.03 per share (Title of Class of Securities) H17182108 (CUSIP Number) Ian F. Smith Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massach |
|
| December 21, 2018 |
Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value CHF 0. |
|
| December 21, 2018 |
Exhibit 1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of common stock, par value CHF 0. |
